EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Distinct clinical characteristics in stage III rectal cancer among different age groups and treatment outcomes after neoadjuvant chemoradiotherapy

Baoqiu Liu, Huilong Luo, Bin Li iD, Haina Yu, Rui Sun, Jibin Li iD, Yuanhong Gao, Peirong Ding, Xicheng Wang, Weiwei Xiao iD

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241229434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 11.02.2024. Verfasst von Baoqiu Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Pro…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: chinese society of clinical oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is a rapidly increasing incidence of early-onset colorectal cancer (EO-CRC) which threatens the survival of young people, while aging also represents a challenging clinical problem.

Objectives

We aimed to investigate the differences in the clinical characteristics and prognosis in stage III rectal cancer (RC), to help optimize treatment strategies. Design and methods: This study included 757 patients with stage III RC, all of whom received neoadjuvant chemoradiotherapy and total mesorectal excision. The whole cohort was categorized as very early onset (VEO, ⩽30 years old), early onset (EO, >30 years old, ⩽50 years old), intermediate onset (IO, >50 years, ⩽70 years), or late onset (LO, >70 years old).

Results

There were more female VEO patients than males, more mucinous adenocarcinoma, signet-ring cell carcinoma, pre-treatment cT4 stage, and higher pre-treatment serum carbohydrate antigen 19-9 compared with the other three groups. VEO patients had the worst survival with the highest RC-related mortality (34.5%), recurrence (13.8%), and metastasis (51.7%). LO patients had the highest non-RC-related mortality rate (16.6%). The Cox regression model showed VEO was a negative independent prognostic factor for disease-free survival [DFS, hazard ratio (HR): 2.830, 95% confidence interval (CI): 1.633–4.904, p < 0.001], distant metastasis-free survival (DMFS, HR: 2.969, 95% CI: 1.720–5.127, p < 0.001), overall survival (OS, HR: 2.164, 95% CI: 1.102–4.249, p = 0.025), and cancer-specific survival (CSS, HR: 2.321, 95% CI: 1.145–4.705, p = 0.020). LO was a negative independent factor on DFS (HR: 1.800, 95% CI: 1.113–2.911, p = 0.017), DMFS (HR: 1.903, 95% CI: 1.150–3.149, p = 0.012), OS (HR: 2.856, 95% CI: 1.745–4.583, p < 0.001), and CSS (HR: 2.248, 95% CI: 1.282–3.942, p = 0.005). VEO patients had better survival in the total neoadjuvant therapy-like (TNT-like) pattern on DFS ( p = 0.039). IO patients receiving TNT-like patterns had better survival on DFS, OS, and CSS ( p = 0.006, p = 0.018, p = 0.006, respectively).

Conclusion

In stage III RC, VEO patients exhibited unique clinicopathological characteristics, with VEO a negative independent prognostic factor for DFS, DMFS, OS, and CSS. VEO and IO patients may benefit from a TNT-like treatment pattern.

Schlagwörter

Stichwörter der Autor:innen

onset ageprognosisrectal cancerstage IIItotal neoadjuvant therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Ca…
  • Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, 19 Nonglin Xia Road, Yue Xiu, Guangzhou 510080, China.
  • Statistical Discipline, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Cente…
  • Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Ca…
  • Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, 19 Nonglin Xia Road, Yuexiu District Guangzhou 510080, China.

ORCID-Profile: Bin Li, Jibin Li, Weiwei Xiao

Förderung

  • chinese society of clinical oncology

Zitieren

APA

Liu, B., Luo, H., Li, B., Yu, H., Sun, R., Li, J., Gao, Y., Ding, P., Wang, X., & Xiao, W. (2024). Distinct clinical characteristics in stage III rectal cancer among different age groups and treatment outcomes after neoadjuvant chemoradiotherapy. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241229434

Vancouver

Liu B, Luo H, Li B, Yu H, Sun R, Li J, et al. Distinct clinical characteristics in stage III rectal cancer among different age groups and treatment outcomes after neoadjuvant chemoradiotherapy. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241229434

BibTeX
@article{Liu2024,
  author = {Liu, Baoqiu and Luo, Huilong and Li, Bin and Yu, Haina and Sun, Rui and Li, Jibin and Gao, Yuanhong and Ding, Peirong and Wang, Xicheng and Xiao, Weiwei},
  title = {Distinct clinical characteristics in stage III rectal cancer among different age groups and treatment outcomes after neoadjuvant chemoradiotherapy},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241229434}
}
Kostenlos starten →